PCRX vs SPY
Pacira BioSciences, Inc. (PCRX) versus SPDR S&P 500 ETF Trust (SPY) — a side-by-side from cached financials, not a winner call.
Pacira BioSciences, Inc. (PCRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
SPDR S&P 500 ETF Trust (SPY) common stock listed on US.
Latest reported PCRX revenue for 2026-06-30 was $369.8M. Net income was $7.6M. PCRX currently screens at market cap $890.8M and trailing P/E 174.2.
SPY does not have a complete income-statement cache yet.
PCRX currently screens at market cap $890.8M and trailing P/E 174.2. SPY currently screens at market cap $0.
Not investment advice. Open the PCRX and SPY stock pages for the full models.
Not investment advice.